
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) and its subsidiary, GW Pharmaceuticals have begun construction of its new, state-of-the-art manufacturing facility at Kent Science Park (KSP) in Sittingbourne, UK, with an investment of over $100 million.
The new facility, expected to be approximately 60,000 sq. ft, is designed to support the company's two regulatory-approved cannabis-based medicines, such as Epidiolex, and to support future capacity for new medicines under development.